BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 20222313)

  • 1. [Monoclonal antibody therapy for non-Hodgkin's lymphoma].
    Paul F; Rossi JF; Cartron G
    Rev Prat; 2010 Jan; 60(1):59-63. PubMed ID: 20222313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.
    Fanale MA; Younes A
    Drugs; 2007; 67(3):333-50. PubMed ID: 17335294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
    Marcus R
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab immunotherapy for non-Hodgkin's lymphoma.
    White CA
    Cancer Biother Radiopharm; 1999 Aug; 14(4):241-50. PubMed ID: 10850310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Monoclonal antibodies in hematology in 2009].
    Bonnet C; Beguin Y; De Prijck B; Witvrouw N; Hustinx R; Fillet G
    Rev Med Liege; 2009; 64(5-6):268-73. PubMed ID: 19642457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
    J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma.
    Witzig TE
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):74-8. PubMed ID: 11226003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma.
    Molina A
    Annu Rev Med; 2008; 59():237-50. PubMed ID: 18186705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.
    King KM; Younes A
    Expert Rev Anticancer Ther; 2001 Aug; 1(2):177-86. PubMed ID: 12113023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab: ongoing and future clinical development.
    Grillo-López AJ; Hedrick E; Rashford M; Benyunes M
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):105-12. PubMed ID: 11842397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving role of rituximab in the treatment of patients with non-Hodgkin's lymphoma.
    Traullé C; Coiffier BB
    Future Oncol; 2005 Jun; 1(3):297-306. PubMed ID: 16556002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituxan immunotherapy and zevalin radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
    White CA
    Curr Pharm Biotechnol; 2003 Aug; 4(4):221-38. PubMed ID: 14529425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
    Witzig TE; Flinn IW; Gordon LI; Emmanouilides C; Czuczman MS; Saleh MN; Cripe L; Wiseman G; Olejnik T; Multani PS; White CA
    J Clin Oncol; 2002 Aug; 20(15):3262-9. PubMed ID: 12149300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel antibodies in the treatment of non-Hodgkin's lymphoma.
    Bhat SA; Czuczman MS
    Neth J Med; 2009 Sep; 67(8):311-21. PubMed ID: 19767657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Proteins in haematology].
    Clarenbach RE; Mey U
    Ther Umsch; 2011 Nov; 68(11):610-7. PubMed ID: 22045523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab (Rituxan/MabThera): the first decade (1993-2003).
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2003 Dec; 3(6):767-79. PubMed ID: 14686699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma.
    Hainsworth JD
    Semin Oncol; 2003 Feb; 30(1 Suppl 2):9-15. PubMed ID: 12652459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
    Collins-Burow B; Santos ES
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma.
    Wiseman GA; Leigh B; Erwin WD; Lamonica D; Kornmehl E; Spies SM; Silverman DH; Witzig TE; Sparks RB; White CA
    Cancer; 2002 Feb; 94(4 Suppl):1349-57. PubMed ID: 11877765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.